TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23469662

Group type: EXPERIMENTAL
Intervention: Transperineal ultrasonic therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (same machine without ultrasound)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Comparison between groups A and B after treatment
Number of subjects: 96
Study: 21334623

Group type: EXPERIMENTAL
Intervention: Nurse-led clinics
Number of subjects: 180

Group type: COMPARATOR
Intervention: Physician-led clinics
Number of subjects: 180
Study: 18687487

Group type: EXPERIMENTAL
Intervention: Rapid access cardiology service (no appointment required)
Number of subjects: 1223

Group type: EXPERIMENTAL
Intervention: Heart failure service (part of the rapid access service)
Number of subjects: 1223
Study: 16969498

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus cystectomy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cystectomy alone
Number of subjects: 94
Study: 14665549

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micro g kg(‐1) h(‐1) + Propofol 6 mg kg(‐1) h(‐1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micro g kg(‐1) h(‐1) + Propofol 3 mg kg(‐1) h(‐1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Vertex‐inion electrode site
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Vertex‐inion electrode site after 30 min of propofol infusion
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Vertex‐mastoid electrodes
Number of subjects: 27
Study: 11240946

Group type: EXPERIMENTAL
Intervention: Low-dose fluticasone propionate (FP) 88 microg (2 puffs of 44 microg) twice daily
Number of subjects: 533
Study: 9252847

Group type: EXPERIMENTAL
Intervention: 0.1 mg octreotide intramuscularly
Number of subjects: 16

Group type: COMPARATOR
Intervention: Secretin stimulation (1 IU/kg intravenous bolus)
Number of subjects: 16
Study: 8238130

Group type: EXPERIMENTAL
Intervention: Antibiotics (ampicillin‐amoxicillin and erythromycin)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 3120568

Group type: EXPERIMENTAL
Intervention: High nitrogen diet (366 mg N/(kg.d))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low nitrogen diet (191 mg N/(kg.d))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 9
Study: 30453553

Group type: EXPERIMENTAL
Intervention: MICRO (5-min microbouts of activity for 9 hours)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ONE (45-min continuous physical activity)
Number of subjects: 22

Group type: COMPARATOR
Intervention: SED (sedentary control condition)
Number of subjects: 22
Study: 27082782

Group type: EXPERIMENTAL
Intervention: Bismuth breast shields
Number of subjects: 101

Group type: COMPARATOR
Intervention: No breast shielding (Control)
Number of subjects: 101
Study: 24989946

Group type: EXPERIMENTAL
Intervention: Abediterol 5 µg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Abediterol 10 µg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Abediterol 25 µg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Abediterol 50 µg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22156609

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 158
Study: 20237219

Group type: EXPERIMENTAL
Intervention: Pragmatic clinical trials, methodological guidance, and coverage with evidence development
Number of subjects: 0
Study: 18485420

Group type: EXPERIMENTAL
Intervention: New test of executive function (selection between stimulus-oriented and stimulus-independent thought)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Classical test of executive function (random response generation)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: New test of executive function
Number of subjects: 15

Group type: COMPARATOR
Intervention: Classical test of executive function
Number of subjects: 15
Study: 15975472

Group type: EXPERIMENTAL
Intervention: Advantec Legacy 20000 with NeoSoniX
Number of subjects: 410

Group type: COMPARATOR
Intervention: Standard Legacy 20000
Number of subjects: 410

Group type: COMPARATOR
Intervention: Advantec Legacy 20000
Number of subjects: 410
Study: 12621276

Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy (AAT) for 15 minutes
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard condition (15 minutes with magazines)
Number of subjects: 35
Study: 10502454

Group type: EXPERIMENTAL
Intervention: Polycose (carbohydrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed meal (equal calories)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study: 7554338

Group type: EXPERIMENTAL
Intervention: Topical salbutamol
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 1961960

Group type: EXPERIMENTAL
Intervention: Propofol as single induction and maintenance hypnotic (group II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thiopental for intravenous induction with oxygen/nitrous oxide (30/70%) for maintenance (group I)
Number of subjects: 20
Study: 7013978

Group type: COMPARATOR
Intervention: BCNU or methyl-CCNU chemotherapy without radiotherapy (Category A)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Whole-brain radiation treatment (6000 rad) with surgery (Category B)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Methyl-CCNU with irradiation
Number of subjects: 115
Study: 30165487

Group type: EXPERIMENTAL
Intervention: Single internal thoracic artery (SITA)
Number of subjects: 905

Group type: COMPARATOR
Intervention: Bilateral internal thoracic artery (BITA)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: SITA
Number of subjects: 905

Group type: COMPARATOR
Intervention: BITA
Number of subjects: 905
Study: 27723134

Group type: EXPERIMENTAL
Intervention: Xamiol® gel once daily as needed (PRN Group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xamiol® gel once daily every day (Continuous group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Xamiol® gel twice weekly (Weekend group)
Number of subjects: 0
Study: 25396266

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 147
Study: 24117666

Group type: EXPERIMENTAL
Intervention: Disulfiram (200 mg daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Adjunctive therapy (mailed letters emphasizing harmful effects of alcohol)
Number of subjects: 109
Study: 22898064

Group type: EXPERIMENTAL
Intervention: Sweet bee venom pharmacopuncture (SBVP)
Number of subjects: 11
Study: 19950569

Group type: EXPERIMENTAL
Intervention: Insulin Aspart (IAsp) with NPH
Number of subjects: 220

Group type: COMPARATOR
Intervention: Human Insulin (HI) with NPH
Number of subjects: 220
Study: 17224915

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0

Group type: COMPARATOR
Intervention: NRT and placebo
Number of subjects: 0
Study: 15548392

Group type: EXPERIMENTAL
Intervention: Transabdominal and transvaginal ultrasonography
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography with magnification
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ultrasonographic evaluation
Number of subjects: 121
Study: 11577304

Group type: EXPERIMENTAL
Intervention: EUS-FNA with suction
Number of subjects: 43

Group type: COMPARATOR
Intervention: EUS-FNA without suction
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Aspiration from the edge of the lymph node
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cytospin-cellblock methods
Number of subjects: 43
Study: 9632001

Group type: EXPERIMENTAL
Intervention: DAB389IL-2 (5, 10, or 15 microg/kg daily intravenously for 3 consecutive days each week for 4 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: DAB389IL-2
Number of subjects: 41
Study: 7891305

Group type: EXPERIMENTAL
Intervention: Itazigrel 5-100 mg (low-dose study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itazigrel 100-600 mg (high-dose study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itazigrel
Number of subjects: 0
Study: 3146890

Group type: EXPERIMENTAL
Intervention: Oxaprotiline
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Crossover phase with oxaprotiline
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Crossover phase with fluvoxamine
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Crossover phase overall response
Number of subjects: 71
Study: 2257065

Group type: EXPERIMENTAL
Intervention: TXA2 synthesis inhibitor, anisodamine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 42
Study: 9919

Group type: EXPERIMENTAL
Intervention: Group psychotherapy (N=50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Individual psychotherapy (N=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both group and individual psychotherapy
Number of subjects: 100
Study: 30771243

Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal insert
Number of subjects: 283

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 283
Study: 27914241

Group type: EXPERIMENTAL
Intervention: Trebananib plus pegylated liposomal doxorubicin (PLD) 50 mg/m2 once every 4 weeks plus weekly intravenous trebananib 15 mg/kg
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo plus pegylated liposomal doxorubicin (PLD) 50 mg/m2 once every 4 weeks
Number of subjects: 223
Study: 25781977

Group type: COMPARATOR
Intervention: Standard regimen annually for 24 months (S1)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Increased dose (800 mg albendazole) annually for 24 months (H1)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Standard dose (300 mg DEC) with increased frequency (6 monthly) (S2)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Increased dose (800 mg albendazole) with increased frequency (H2)
Number of subjects: 104
Study: 23429871

Group type: EXPERIMENTAL
Intervention: Initial arrival at high altitude (days 2-4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Days 12-15 at high altitude
Number of subjects: 12
Study: 21155776

Group type: EXPERIMENTAL
Intervention: 12-session manualized TF-CBT
Number of subjects: 64

Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 64
Study: 20095375

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b, 3 million IU, administered rectally on chemotherapy days (twice weekly) for 4 months or more
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no immunomodulator)
Number of subjects: 70
Study: 17119538

Group type: EXPERIMENTAL
Intervention: Farampator (500 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15292668

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCA)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Other antidepressants
Number of subjects: 209
Study: 11698326

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine/propofol (2.5 mg.kg(‐1)*hr(‐1) S(+)‐ketamine, 1.5‐2.5 microg*mL(‐1) propofol)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sevoflurane (2.0 MAC, 4.0 %)
Number of subjects: 24
Study: 9150314

Group type: EXPERIMENTAL
Intervention: Co-cultures with autologous alveolar macrophages (AMs) from patients with IPF
Number of subjects: 6

Group type: COMPARATOR
Intervention: Co-cultures with autologous AMs from normal volunteers (5 nonsmokers and 4 smokers)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: IL-10 treatment in co-cultures with AMs from healthy volunteers
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: IL-10 treatment in co-cultures with AMs from patients with IPF
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Expression of CD80 and CD86 on AMs from patients with IPF and normal volunteers
Number of subjects: 6
Study: 7950123

Group type: EXPERIMENTAL
Intervention: Transscleral suture fixation of the posterior chamber lens
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (uncomplicated cataract extraction)
Number of subjects: 34
Study: 3296136

Group type: EXPERIMENTAL
Intervention: levamisole
Number of subjects: 50
Study: 29697799

Group type: EXPERIMENTAL
Intervention: 2014
Number of subjects: 53439

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 53439

Group type: EXPERIMENTAL
Intervention: More educated individuals
Number of subjects: 53439

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 53439

Group type: EXPERIMENTAL
Intervention: Country size
Number of subjects: 53439

Group type: EXPERIMENTAL
Intervention: 2014 willingness to travel
Number of subjects: 53439
Study: 28455085

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen 1000 mg every 8 hours for 48 hours (total of 6 doses)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (100 mL saline) every 8 hours for 48 hours (total of 6 doses)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 26790216

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electric stimulation (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham-acupoint (group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Blank control (group C)
Number of subjects: 90
Study: 23782729

Group type: EXPERIMENTAL
Intervention: Moderate therapeutic hypothermia (33°C ± 1) over at least 72 hours in addition to early decompressive hemicraniectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional outcome assessment at day 14 and at 12 months follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complications related to hypothermia
Number of subjects: 0
Study: 21164304

Group type: COMPARATOR
Intervention: Intravenous sedation (IVS)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine (IAL)
Number of subjects: 63
Study: 18234557

Group type: EXPERIMENTAL
Intervention: AIM-BpTRU system
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: AIM-Spacelabs system
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 17
Study: 17024938

Group type: EXPERIMENTAL
Intervention: Single‐Bond + Filtek‐Flow + Filtek Z250
Number of subjects: 19

Group type: COMPARATOR
Intervention: Single‐Bond + Filtek Z250
Number of subjects: 19
Study: 12777347

Group type: EXPERIMENTAL
Intervention: Participants reporting general trauma (n=38)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Participants reporting childhood sexual abuse (n=15)
Number of subjects: 96
Study: 10551154

Group type: EXPERIMENTAL
Intervention: Scaling with adjunctive antimicrobial therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Full mouth scaling alone
Number of subjects: 34
Study: 8752776

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of 20 micrograms.h-1 of buprenorphine (Bu) with additional 20 micrograms of Bu
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of 20 micrograms.h-1 of Bu plus 1 mg.h-1 of bupivacaine (Bup) with additional 20 micrograms of Bu plus 1 mg of Bup
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of 20 micrograms.h-1 of Bu plus 2 mg.h-1 of Bup with additional 20 micrograms of Bu plus 2 mg of Bup
Number of subjects: 21

Group type: COMPARATOR
Intervention: Self controlled analgesia system (control group)
Number of subjects: 21
Study: 1899206

Group type: EXPERIMENTAL
Intervention: Closed-loop control of blood pressure
Number of subjects: 74

Group type: COMPARATOR
Intervention: Manual control of blood pressure
Number of subjects: 74
Study: 6312942

Group type: EXPERIMENTAL
Intervention: Active hemodialysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham hemodialysis
Number of subjects: 8
Study: 29510791

Group type: EXPERIMENTAL
Intervention: Sleep education website (Sleep to Stay Awake); intervention duration: 8 weeks; participants completed surveys at baseline, 1 week, and 8 weeks.
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Sleep education website (Sleep to Stay Awake); intervention duration: 8 weeks.
Number of subjects: 549
Study: 26747051

Group type: EXPERIMENTAL
Intervention: APOL1 genetic testing at baseline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control (APOL1 genetic testing at one year)
Number of subjects: 0
Study: 25329552

Group type: EXPERIMENTAL
Intervention: Head Start
Number of subjects: 3790

Group type: COMPARATOR
Intervention: Other center-based care
Number of subjects: 3790
Study: 23192781

Group type: EXPERIMENTAL
Intervention: Gadoxetate disodium (10 mL, n = 97; 8 mL, n = 1; 16 mL, n = 1)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Gadobenate dimeglumine (0.1 mmol per kilogram of body weight, maximum dose, 20 mL)
Number of subjects: 192
Study: 21126389

Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride (1 mg, im, q. 12 h)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 18503218

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (10 mg/kg orally, 3 times per week for 12 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation and untreated control group
Number of subjects: 20
Study: 15904591

Group type: EXPERIMENTAL
Intervention: Bilateral rectus sheath block (BRSB) with 25 mg of bupivacaine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intraperitoneal (IP) instillation of 25 mg of bupivacaine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Intraincisional (II) instillation of 25 mg of bupivacaine
Number of subjects: 91
Study: 12580839

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100-150 mg/day for five days starting from day 2 of the cycle and 150 IU of hMG/day on days 6-10, GnRH antagonist (Centrorelix) 0.25 mg/day started when the leading follicle reached 16 mm in the absence of an LH surge
Number of subjects: 189

Group type: COMPARATOR
Intervention: Long-acting GnRH agonist (Deacapeptyl) 0.1 mg/day as standard long protocol
Number of subjects: 189
Study: 10459624

Group type: COMPARATOR
Intervention: 3 MU of interferon alpha-2b, three times a week for 6 months (Group A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 3 MU of interferon alpha-2b plus 600 mg/day of ribavirin for 6 months (Group B)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Group B (ribavirin)
Number of subjects: 62
Study: 7484855

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study: 2349553

Group type: EXPERIMENTAL
Intervention: Pulsatile flow (n = 8)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonpulsatile flow (n = 14)
Number of subjects: 22
Study: 498828

Group type: EXPERIMENTAL
Intervention: Quinidine (200 mg every six hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procainamide (500 mg every four hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (neither drug)
Number of subjects: 0
Study: 28511669

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg once daily for 12 months
Number of subjects: 472
Study: 25761006

Group type: EXPERIMENTAL
Intervention: FC-added rtfMRI-NF
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional activity-based rtfMRI-NF
Number of subjects: 14
Study: 23500254

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 420

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 420
Study: 21326075

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 49
Study: 19289710

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray, 200 microg once daily
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 17021664

Group type: EXPERIMENTAL
Intervention: Ga‐As‐Al laser treatment applied over three trigger points bilaterally for 2 min over each point once a day for 15 days during a period of 3 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo treatment (laser instrument switched off) applied over the same protocol as the intervention group
Number of subjects: 64
Study: 15215114

Group type: EXPERIMENTAL
Intervention: 3.5% Salicylic Acid (SA)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 1% Salicylic Acid (SA) with 3.5% Pyroglutamic Acid (PGA)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 4% Pyroglutamic Acid (PGA)
Number of subjects: 58
Study: 11515948

Group type: EXPERIMENTAL
Intervention: Labial infiltration of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Labial infiltration of 1.8 mL of 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lingual infiltration of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Labial infiltration of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Labial infiltration of 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lingual infiltration of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 80
Study: 9629963

Group type: EXPERIMENTAL
Intervention: Vertical and oblique bar stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orientation 'entropy' measure (height-to-width ratio)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model of orientation coding
Number of subjects: 0
Study: 8908388

Group type: EXPERIMENTAL
Intervention: Normal albuminuria (< 20 micrograms/min)
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Microalbuminuria (20‐200 micrograms/min)
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: Overt albuminuria (> 200 micrograms/min)
Number of subjects: 947

Group type: EXPERIMENTAL
Intervention: UAE (Urinary Albumin Excretion)
Number of subjects: 947